New hope for hard-to-treat breast cancer: phase 3 trial launches
NCT ID NCT06957886
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called BL-M07D1 against standard chemotherapy in 566 adults with HER2-low breast cancer that has come back or spread. The goal is to see if BL-M07D1 can slow the cancer's growth better than current treatments. Participants must be women aged 18 to 75 with confirmed HER2-low status.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-LOW BREAST CANCER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, Hunan, China
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental HER2 cancer drug trial halted early
- New combo aims to tackle Hard-to-Treat breast cancer
- New targeted pill takes aim at Hard-to-Treat cancers
- New drug shows promise for Hard-to-Treat breast cancers in Real-World study
- New scan could match breast cancer patients to best therapy
- Can switching drugs outsmart breast cancer? new trial tests two targeted therapies